- Home
- FIGS vs ANAB Comparison
FIGS vs ANAB Comparison
Compare FIGS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- ANAB
- Stock Information
- Founded
- FIGS 2013
- ANAB 2005
- Country
- FIGS United States
- ANAB United States
- Employees
- FIGS N/A
- ANAB N/A
- Industry
- FIGS Apparel
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- ANAB Health Care
- Exchange
- FIGS Nasdaq
- ANAB Nasdaq
- Market Cap
- FIGS 776.0M
- ANAB 759.5M
- IPO Year
- FIGS 2021
- ANAB 2017
- Fundamental
- Price
- FIGS $4.58
- ANAB $18.55
- Analyst Decision
- FIGS Hold
- ANAB Buy
- Analyst Count
- FIGS 5
- ANAB 10
- Target Price
- FIGS $5.35
- ANAB $36.38
- AVG Volume (30 Days)
- FIGS 2.4M
- ANAB 928.3K
- Earning Date
- FIGS 05-08-2025
- ANAB 05-08-2025
- Dividend Yield
- FIGS N/A
- ANAB N/A
- EPS Growth
- FIGS N/A
- ANAB N/A
- EPS
- FIGS 0.02
- ANAB N/A
- Revenue
- FIGS $555,558,000.00
- ANAB $91,280,000.00
- Revenue This Year
- FIGS $1.13
- ANAB N/A
- Revenue Next Year
- FIGS $4.62
- ANAB $59.43
- P/E Ratio
- FIGS $292.38
- ANAB N/A
- Revenue Growth
- FIGS 1.82
- ANAB 432.03
- 52 Week Low
- FIGS $4.18
- ANAB $12.21
- 52 Week High
- FIGS $7.06
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- FIGS 42.59
- ANAB 56.46
- Support Level
- FIGS $4.52
- ANAB $17.50
- Resistance Level
- FIGS $5.01
- ANAB $19.60
- Average True Range (ATR)
- FIGS 0.23
- ANAB 1.35
- MACD
- FIGS 0.04
- ANAB 0.20
- Stochastic Oscillator
- FIGS 47.04
- ANAB 58.89
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).